Nutlin-3

製品コードS1061

Nutlin-3化学構造

分子量(MW)：581.5

Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

サイズ 価格(税別)  
JPY 30710.00
JPY 18260.00
JPY 28220.00
JPY 61420.00
JPY 161020.00
お問い合わせ バルク問合せ

文献中Selleckの製品使用例(11)

カスタマーフィードバック(5)

  • Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

    Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

     

    p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

    Cell Death Dis 2012 3, e294. Nutlin-3 purchased from Selleck.

  • J Cell Physiol, 2018, 233(9):7424-7434. Nutlin-3 purchased from Selleck.

    Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

    Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.

  • d qPCR evaluation of DKK1 in MSCs exposed to melphalan in combination with increasing concentrations of nutlin-3 for 24 h. Cells were pre-treated with nutlin-3 for 20 min prior to chemotherapy. *Indicates p value<0.05, One-way ANOVA with Holm-Sidak post hoc

    Med Oncol, 2016, 33(10):113. Nutlin-3 purchased from Selleck.

製品安全説明書

Mdm2阻害剤の選択性比較

生物活性

製品説明 Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.
ターゲット
Mdm2 [5]
(Cell-free assay)
180 nM
体外試験

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]
細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rVdFXDqM7:TR?= MlXXOFjDqGh? MYLicI9kc3NiMketU2hENWmwZIXj[YQh[2WubDDwdo9tcW[ncnH0bY9vKGOxbYDhdoFjdGVidH:geIhifCCxZjDiZZNidCCuZY\lcJM> MkniNlY{PTB3NkW=
NP69 M3O5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\1eIF2UUN3ME2zNU43QcLzMj61OEDPxE1? M4\ScVI3OjV{NUe1
NP460 MlOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLlelJJUUN3ME2yNk45PcLzMT6xPEDPxE1? MY[yOlI2OjV5NR?=
C666-1 M4DwdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3K5ZmlEPTB;MUmuPVXDuThwOUOg{txO NIrydHczPjJ3MkW3OS=>
C666-1 NWjZOVdSS2WubDDWbYFjcWyrdImgRZN{[Xl? NW\wOXE1OTBiwsXN NYHqWpRtPDhiaB?= M1nzb2ROW09? NFLRO2V{\W6|aYTpfoV{KEN4Nk[tNUBk\WyuczD0c{B1cGViY4n0c5RwgGmlIHXm[oVkfCCxZjDjbZNxdGG2aX6= NEDSTpUzPjJ3MkW3OS=>
C666-1  NVPXcVdyTnWwY4Tpc44hSXO|YYm= MkXENVAhyrWP Mmr1NlQhcA>? M3\tTmROW09? Mn;xZYN1cX[jdHXzJJRp\SCyNUOgdIF1cHejeTygeZBz\We3bHH0bY5oKHB3MzygdFIyKGGwZDDN[I0z M3vQd|I3OjV{NUe1
C666-1 NUfieWJKSXCxcITvd4l{KEG|c3H5 M2OwTVExKML3TR?= NIX5TpE1QC95MjDo MnjuSG1UVw>? M{XCdpNmdnOrdHn6[ZMhSzZ4Nj2xJINmdGy|IITvJINqe3CuYYTpck1qdmS3Y3XkJIFxd3C2b4Ppdy=> M{jBVFI3OjV{NUe1
A549 NWPpOGJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\X[VI1KGh? M1TTdWlEPTB;MUeuOlghyrFiND61NkDPxE1? NI\2WYszPjF{NUKzNC=>
A549-NTC MmTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWeyOEBp MUTJR|UxRTF7LkSyJOKyKDFwOU[g{txO NHjmXVMzPjF{NUKzNC=>
A549-920 MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4L2bVI1KGh? Mn;WTWM2OD1|Mz64OUDDuSB2Lki0JO69VQ>? NInjc3czPjF{NUKzNC=>
CRL-5908 M1njUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI[1TYUzPCCq MXXJR|UxRTN6LkexJOKyKDJwNEOg{txO MV2yOlEzPTJ|MB?=
L6 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHnVnMyOMLizszNxsA> Ml;SNlQwPDhxN{KgbC=> NITnNWdFVVOR NVPaNFZjcW6qaXLpeJMh[2WubIOgdJJwdGmoZYLheIlwdiCjbnSg[Iln\mW{ZX70bYF1cW:w MUCyOVg4OTd7NB?=
C2C12 M1H1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1noXVExyqEQvF5CpC=> NYfPfolYOjRxNEivO|IhcA>? NVnZRXJCTE2VTx?= NGH1PGVqdmirYnn0d{Bk\WyuczDwdo9tcW[ncnH0bY9vKGGwZDDkbYZn\XKnboTpZZRqd25? NYjMT2o3OjV6N{G3PVQ>
MCF-7  Mn\RSpVv[3Srb36gRZN{[Xl? MUSxNOKh|ryP NEjNcWJFVVOR NXj5UohUcW6qaXLpeJMh[3mlbHnuJGQyKGGwZDDEbYNmesLi MVuyOVcxOjdyMx?=
DU4475  MYnGeY5kfGmxbjDBd5NigQ>? NWK2dJU1PS9zMD:yNEDPxE1? MVqyOOKhcA>? NXTlVG1Q\G:5boLl[5Vt[XSnczDUc4NiNTFiZH;z[UBl\XCnbnTlcpRtgQ>? M1jPPVI2PTR5MUe0
SMMC-7721 MV3GeY5kfGmxbjDBd5NigQ>? MVKxNEDPxE1? MlPjOFghcA>? NYTVRnhVTE2VTx?= MofpZ4F2e2W|IFTORUBFW0JiZHHtZYdm NXe0cVQ{OjV3NESzOlE>
SMMC-7721 M1nVfWZ2dmO2aX;uJGF{e2G7 Mk\YNVAh|ryP NIHWOng1QCCq NWXZe|dnTE2VTx?= MXXpcoR2[2W|IITo[UBkcHKxbXH0bY4u[m:3bnSgdJJwfGWrbjDJSmkyPiC2bzDwZZJ1cWGubImgcI9k[WyrenWgbY4hfGinIHP5eI9xdGG|bdMg Ml3zNlU2PDR|NkG=
SMMC-7721 Mmq0SpVv[3Srb36gRZN{[Xl? NITz[2syOCEQvF2= MoPROFghcA>? MX\EUXNQ NVX5S5IycW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mxsBKTk6EMdMgcXJPSQ>? NIrOcVgzPTV2NEO2NS=>
SMMC-7721 M3Gxb2Z2dmO2aX;uJGF{e2G7 NVTyfHE1OTBizszN MV[zOkBp M4rYfmROW09? NUfPT4Zv[2G3c3XzJJRp\SCnY4TvdIlkKGW6cILld5Nqd25ib3[gTWZKOTZ? NFLGfmUzPTV2NEO2NS=>
MCF-7 M13JbGZ2dmO2aX;uJGF{e2G7 MknENVDDqM7:TR?= NGTmT5MxNTJ2IHi= MoKxbY5lfWOnczDwOVMh[W6mIICyNU9EcXBz NVXPfHFMOjV2OEKzO|M>
OVCAR10 Mk\vSpVv[3Srb36gRZN{[Xl? MkfaNVDDqM7:TR?= M1O0U|IycMLi NXToPXN4TE2VTx?= MUTpcoNz\WG|ZYOgdFU{KHC{b4TlbY4hdGW4ZXzz M{HxblI2PDJ4NUS4
NCI-H23 M{i0N2Z2dmO2aX;uJGF{e2G7 NUP0TodvOTEEoN88US=> MlTBNlFpyqB? NXXST3FoTE2VTx?= M4XMdIlv[3KnYYPld{BxPTNicILveIVqdiCuZY\lcJM> MXKyOVQzPjV2OB?=
A2780 MkHISpVv[3Srb36gRZN{[Xl? NU\SZZg6OTEEoN88US=> NHW0fmMzOWkEoB?= MYfEUXNQ MVnpcoNz\WG|ZYOgdFU{KHC{b4TlbY4hdGW4ZXzz MXOyOVQzPjV2OB?=
NCI-H23 M1raPWZ2dmO2aX;uJGF{e2G7 NGfiW2gyOMLizszN MkDSNlFpyqB? NEDFSmpFVVOR MYnk[YNz\WG|ZYOgeIhmKE[xeF2xJIxmfmWucx?= MWqyOVQzPjV2OB?=
A2780 NYTL[21QTnWwY4Tpc44hSXO|YYm= M4rpUlExyqEQvF2= NHzYeFMzOWkEoB?= NETnXoVFVVOR NHP5[mdl\WO{ZXHz[ZMhfGinIF\vfG0yKGyndnXsdy=> M{TkVFI2PDJ4NUS4
HCT116  M17SemZ2dmO2aX;uJGF{e2G7 MonmNVAhyrWP MnntNlQhcA>? NUDM[oxC[2G3c3XzJIEheDV|LXTldIVv\GWwdDD0[ZRz[XCub3nkJGcyNWG{cnXzeEBqdiCmaYDsc4llKEiFVEGxOkBkdG:wZYOgSFMh[W6mIFS4 NIiwZY0zPTN6MEC1OS=>
MCF-10CA1a M1PRdWZ2dmO2aX;uJGF{e2G7 M3PRRlExyqEQvF2= NEDTNZI1QCCq Mn7sSG1UVw>? M3nLNYlvcGmkaYTzJIJie2GuIHnueoF{cW:wIHHu[EBz\WS3Y3XkJHRITi4QskOtbY5lfWOnZDDpcpZie2mxbjD0c{Bj[XOjbDDs[ZZmdHN? M2PFdlI2OjV5N{K5
MCF-10A1  NV\FNYtRTnWwY4Tpc44hSXO|YYm= NYe3VHc2OTEEoN88US=> NU\EZlZ6OjRxNEigbC=> NIPBT5RFVVOR NFXjbHhqdmirYnn0d{BucWe{YYTpc44hd2Zibn;ycYFtKGK{ZXHzeEBmeGm2aHXsbYFtyqB? NVnaOnlPOjV{NUe3Nlk>
MCF-10CA1a MXzGeY5kfGmxbjDBd5NigQ>? NYTxUFhLOTEEoN88US=> MoTWNlQhcA>? NFnsR4JFVVOR M3LCT4Rm[3KnYYPld{B1cGViVFfGMe6zOy2rbnT1Z4VlKG2UTlGgcIV3\Wy|IH;mUW1ROi{EoF3NVFktKGGwZNMgbY51\We{aX9CpO6zyqB| NWPDdmU1OjV{NUe3Nlk>
MCF-10CA1a M2DiTWZ2dmO2aX;uJGF{e2G7 MWexNOKh|ryP NWnITndZOjRiaB?= Ml\tSG1UVw>? M1LMTIlvcGmkaYTzJEBVT0ZvzsKzMYlv\HWlZXSgSXBJSjMEoH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= MXyyOVI2Pzd{OR?=
SK-BR-7 MVjGeY5kfGmxbjDBd5NigQ>? NXe5UpVsOTEEoN88US=> MXOyOEBp NWOzbZhLTE2VTx?= M3fiWIlvcGmkaYTzJEBVT0ZvzsKzMYlv\HWlZXSgSXBJSjMEoH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= NFXs[IwzPTJ3N{eyPS=>
SUM102PT NHzITIhHfW6ldHnvckBCe3OjeR?= NFTLV|gyOMLizszN M4G1RlI1KGh? NXLHcnNXTE2VTx?= M2Tye4lvcGmkaYTzJEBVT0ZvzsKzMYlv\HWlZXSgSXBJSjMEoH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= NVPGXW5uOjV{NUe3Nlk>
RAW 264.7 MY\GeY5kfGmxbjDBd5NigQ>? NIPHS4YyOMLizszN NVHTZ2diOzBibXnu NFHE[3dxemW4ZX70d{B1cGVicEWzJJJm\HWldHnvckBqdiC{ZYPwc45{\SC2bzDMVHM> MlOxNlUyPzJ3NEe=
RAW 264.7 MmrWSpVv[3Srb36gRZN{[Xl? NHjqO24yOMLizszN M1zKbFMxKG2rbh?= NWj1bpd1emWmdXPld{B1cGViTGDTMYF2\22nboTl[EB1cGViTl[t{tpDKGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBi[3Srdnn0fS=> MUmyOVE4OjV2Nx?=
RAW 264.7 M3HQVGZ2dmO2aX;uJGF{e2G7 M2\lclExyqEQvF2= MXGzNEBucW5? M{T5bIlvcGmkaYTzJGxRWy2rbnT1Z4VlKE6RIIDyc4R2[3Srb39CpC=> MoXzNlUyPzJ3NEe=
MCF7  Mm\0R4VtdCCYaXHibYxqfHliQYPzZZk> NUK2bIY2Oi53INM1US=> NGfsc5A2KGR? Ml7iSG1UVw>? NX74RWtPe2Wwc3n0bZpmeyCPQ1[3JJRwKFCDUmCgbY5pcWKrdHnvci=> Mmr6NlUxQDV7MEK=
MCF7  NUjrc|JVTnWwY4Tpc44hSXO|YYm= MVOyMlUhyrWP NFTvUIk1QCCq MkTjSG1UVw>? NHXSWW9l\WO{ZXHz[ZMhfGinIHjvcY9td2exdYOgSHNDKHKncHHpdkBnemWzdXXuZ4lmew>? Mo\xNlUxQDV7MEK=
ACHN Ml:4R4VtdCCYaXHibYxqfHliQYPzZZk> NFWyUVAxNjVvMUCg{txO MU[wMVYh\A>? MoTuSG1UVw>? NW\mdZhIcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MmizNlUxPjd5OEe=
Caki-2 NHzDcXhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2jCS|AvPS1zMDFOwG0> MUKwMVYh\A>? NIPtTopFVVOR NXfaN4xCcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Mn7XNlUxPjd5OEe=
A498 NIPoVHlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MVuwMlUuOTBizszN MWewMVYh\A>? NGrGW5lFVVOR MX;pcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NXnicJhZOjVyNke3PFc>
115 NUfaTJEyS2WubDDWbYFjcWyrdImgRZN{[Xl? NWTHSGxDOC53LUGwJO69VQ>? NUXtUlZmOC14IHS= NYHvVHpsTE2VTx?= Mk\PbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M{PoZlI2ODZ5N{i3
117 MXHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mo\oNE42NTFyIN88US=> M4\pd|AuPiCm NH\sSlVFVVOR MYTpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M3Kzc|I2ODZ5N{i3
ACHN NFLjZZhHfW6ldHnvckBCe3OjeR?= NIPZfYoxNjVxMT:1JO69VQ>? M3qwWVQ5KGh? MnLnSG1UVw>? MVXs[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? NF34NG4zPTB4N{e4Oy=>
Caki-2 M{HTfmZ2dmO2aX;uJGF{e2G7 NV;SeoJsOC53L{GvOUDPxE1? NE[2cnA1QCCq MVnEUXNQ NGDJVJNt\WGmczD0c{BqdmO{ZXHz[YQh\XiycnXzd4lwdiCxZjDwOVMh[W6mIIPvcYUheDV|IIThdodmfCCpZX7ld|ohVUSPMjygZY5lKHB{MR?= NHLucWwzPTB4N{e4Oy=>
A498 MVjGeY5kfGmxbjDBd5NigQ>? Mn\0NE42NzFxNTFOwG0> NEnFOYg1QCCq M{XqcGROW09? NYm4V|UxdGWjZIOgeI8hcW6lcnXhd4VlKGW6cILld5Nqd25ib3[gdFU{KGGwZDDzc41mKHB3MzD0ZZJo\XRiZ3Xu[ZM7KE2GTUKsJIFv\CCyMkG= MXmyOVA3Pzd6Nx?=
115 NV;5ZWw{TnWwY4Tpc44hSXO|YYm= M3r4[VAvPS9zL{Wg{txO NHmwZo81QCCq MXzEUXNQ NHznfFVt\WGmczD0c{BqdmO{ZXHz[YQh\XiycnXzd4lwdiCxZjDwOVMh[W6mIIPvcYUheDV|IIThdodmfCCpZX7ld|ohVUSPMjygZY5lKHB{MR?= NX;M[GtpOjVyNke3PFc>
ACHN MkKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmC5OUDPxE1? M4HDeFQ5KGh? MVTEUXNQ NIjBO|lqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0xsA> M1TwXVI2ODZ5N{i3
Caki-2 M4rodGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXxW4o2KM7:TR?= MkXpOFghcA>? MonjSG1UVw>? MlX3bY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg M1HpSFI2ODZ5N{i3
A498 Mk\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWe1JO69VQ>? M2XqTFQ5KGh? NY\3UG9ITE2VTx?= NYLXXplwcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeOKh MmnENlUxPjd5OEe=
115 NHLBZ5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;6OUDPxE1? MWG0PEBp NELrWYxFVVOR Mlu5bY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg NEO1WFYzPTB4N{e4Oy=>
ACHN NI[4So5HfW6ldHnvckBCe3OjeR?= MkHiOUDPxE1? MWC0PEBp MX;EUXNQ M{OycIlv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC= NWLle2xrOjVyNke3PFc>
Caki-2 NYno[nVqTnWwY4Tpc44hSXO|YYm= NHPKN2Y2KM7:TR?= NV\3UXVlPDhiaB?= M4\HOmROW09? M3nYN4lv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC= NFfSWVEzPTB4N{e4Oy=>
A498 Ml:3SpVv[3Srb36gRZN{[Xl? M{\5NlUh|ryP NH7WS5c1QCCq NWDGeI9ITE2VTx?= MlvLbY5lfWOnczDwOVMu\GWyZX7k[Y51KHOnbnXzZ4Vv[2YEoB?= Mlv4NlUxPjd5OEe=
115 Ml7BSpVv[3Srb36gRZN{[Xl? NHTzUpo2KM7:TR?= NVrBcoh5PDhiaB?= NHzZOpdFVVOR MVzpcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi M2K3SVI2ODZ5N{i3
MOLM-13 NWjKT3pYTnWwY4Tpc44hSXO|YYm= NEjwWm03yqEQvF2= NVX3cpp2OC16IHi= MYjEUXNQ NWrIcXV{cW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gdFU{NCCPRF2yMEBxOjFiYX7kJIFk\XS7bHH0[YQheDV| M2LjXlI1QDh3MEiy
MOLM-13 NWD5e3ljTnWwY4Tpc44hSXO|YYm= MmO4OuKh|ryP NGiwfIg3KGh? MUHEUXNQ Mnrq[Y5p[W6lZYOgeIhmKGGlZYT5cIF1cW:wIH;mJIhqe3SxbnWgTFJDKGGwZDDo[YF1KHOqb3PrJJBzd3SnaX7zJGh{eDJ5IHHu[EBJe3B7MB?= MojYNlQ5QDVyOEK=
HepG2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXZO|IhcA>? NELBclJFVVOR NX;SPHduUUN3ME2zOU45PiEEsTCyMlkh|ryP MlLlNlQ5QDR6MEm=
HepG2/As NWDvUHl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILyWpM4OiCq MUHEUXNQ MVfJR|UxRTZ6LkGzJOKyKDlwNjFOwG0> MXGyOFg5PDhyOR?=
SMMC7721 NHT1NIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\1O|IhcA>? MULEUXNQ MlfQTWM2OD1|MT6yPEDDuSB2LkKg{txO NIn2NFgzPDh6NEiwPS=>
SMMC7721/Ac MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3FWpM2PzJiaB?= M1:4TmROW09? M3TGVmlEPTB;NUWuNlEhyrFiNT6wN{DPxE1? MVuyOFg5PDhyOR?=
Huh-7 NVX5Rm5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYr2NFNQPzJiaB?= NGftZpdFVVOR MonzTWM2OD1|Mz65OkDDuSB|Lkmg{txO NWjibGVkOjR6OES4NFk>
Hep3B NFi3Z3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWm3NkBp NF[wUYVFVVOR MXrJR|UxRTJyLkG4JOKyKDFwOESg{txO NHfMR2ozPDh6NEiwPS=>
HepG2 MX;BdI9xfG:|aYOgRZN{[Xl? MomybY5lfWOnczDhdI9xfG:|aYO= Moj6NlQ5QDR6MEm=
SMMC7721 MXPBdI9xfG:|aYOgRZN{[Xl? M4rFfIlv\HWlZYOgZZBweHSxc3nz NVTN[I9SOjR6OES4NFk>
Huh-7 NWTaWJFGSXCxcITvd4l{KEG|c3H5 MmD0bY5lfWOnczDhdI9xfG:|aYO= NHf4bVQzPDh6NEiwPS=>
Hep3B NYjrbFFOSXCxcITvd4l{KEG|c3H5 MnWwbY5lfWOnczDhdI9xfG:|aYO= NYDlcXQ4OjR6OES4NFk>
U2OS  NXXMRWljTnWwY4Tpc44hSXO|YYm= MWWyNEDPxE1? NX6zUIRGOjRiaB?= MoHBbY5kemWjc3XzJJRp\SCvUl7BJIxmfmWuczDv[uKhSkOOMlGxMEBDS0y[TNMgZY5lSkOOVx?= NIfHXnAzPDh4N{K1PS=>
AML2 MmD2RZBweHSxc3nzJGF{e2G7 M1;XeVIwOTBizszN NYLvUVd1OjRxNEigbC=> NGC4b4NqdmS3Y3XzJIFxd3C2b4Ppdy=> M4G1WVI1PjV7N{S5
MOML13 M1;KZmFxd3C2b4Ppd{BCe3OjeR?= MVOyM|ExKM7:TR?= M2HoZ|I1NzR6IHi= MnzybY5lfWOnczDhdI9xfG:|aYO= NEjsNGMzPDZ3OUe0PS=>
AML2 MmXlSpVv[3Srb36gRZN{[Xl? MWexNO69VQ>? MYGyM|QhcA>? MX7pcoNz\WG|ZYOgeIhmKGyndnXsJI9nKHB3Mx?= NV\UWYpwOjR4NUm3OFk>
AML3 NUDuTmdlTnWwY4Tpc44hSXO|YYm= MYKxNO69VQ>? NYTDeWFzOi92IHi= MV7pcoNz\WG|ZYOgeIhmKGyndnXsJI9nKHB3Mx?= NYHi[YdLOjR4NUm3OFk>
MOML13 NH:y[2FHfW6ldHnvckBCe3OjeR?= MVmxNO69VQ>? M{TXd|IwPCCq MkjsbY5kemWjc3XzJJRp\SCuZY\lcEBw\iCyNUO= Mo\VNlQ3PTl5NEm=
BeWo MkDlSpVv[3Srb36gRZN{[Xl? MVizNEDDvU1? NYHtVWFbOjRiaB?= NGjDS|dqdmO{ZXHz[ZMheDV|LDDN[I0zNCCyMkGgZY5lKFC3bXGgZZQhfGinIIDyc5RmcW5ibHX2[Yw> M2[2SlI1PDl6MUW0
BeWo NVSwcoZlSXCxcITvd4l{KEG|c3H5 NWLVcHJVOzBiwsXN MYGyOEBp MUHpcoNz\WG|ZYOgZZBweHSxc3nz M3iy[FI1PDl6MUW0
OCI Mnf3SpVv[3Srb36gRZN{[Xl? MkP3NVAh|ryP MnuyNlQhcA>? NYCzem1sfXC{ZXf1cIF1\XNidHjlJHNQS1NvMTDlfJBz\XO|aX;u NU\zSW45OjR2N{O1OlI>
MOLM MYDGeY5kfGmxbjDBd5NigQ>? NUK1fWhmOTBizszN NYjqSo1{OjRiaB?= MUD1dJJm\3WuYYTld{B1cGViU1;DV{0yKGW6cILld5Nqd25? MmLaNlQ1PzN3NkK=
U2OS  NEDKOVJHfW6ldHnvckBCe3OjeR?= M1;ZT|IxKM7:TR?= MVmyOEBp M2C4[4lv[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBJVy1zIIDyc5RmcW5iYYOge4VtdCCjczD0bIUheDV|IIDyc5RmcW5? NUj0V4FxOjR|Nk[wNFc>
RKO MkC3SpVv[3Srb36gRZN{[Xl? NYHidnZSOjBizszN MmT2NlQhcA>? Mn\LbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZidHjlJGhQNTFicILveIVqdiCjczD3[YxtKGG|IITo[UBxPTNicILveIVqdg>? M2XC[|I1OzZ4MEC3
U2OS  M1vJRWZ2dmO2aX;uJGF{e2G7 MnvzNlAh|ryP M3Pp[|I1KGh? MVLpcoR2[2W|IFjPMVEh\XiycnXzd4lwdiCjdDD0bIUhdGW4ZXygc4YhfHKjboPjdolxfGmxbh?= MmG4NlQ{PjZyMEe=
RKO MmfOSpVv[3Srb36gRZN{[Xl? MX:yNEDPxE1? NH6yN5YzPCCq MmLybY5lfWOnczDIU{0yKGW6cILld5Nqd25iYYSgeIhmKGyndnXsJI9nKHS{YX7zZ5JqeHSrb36= NVfhRoRwOjR|Nk[wNFc>
SMMC-7721  NHzpWI1E\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1XnN|EvOjVvMkCg{txO NY\FcXY4OjRxNEivO|IhcA>? MV;EUXNQ MULpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= MWmyOFI5PjNzMh?=
HuH-7 MkLTR4VtdCCYaXHibYxqfHliQYPzZZk> NGf0eVMyNjJ3LUKwJO69VQ>? MnXBNlQwPDhxN{KgbC=> M3S3UmROW09? MVjpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= MoK2NlQzQDZ|MUK=
SMMC-7721  MlPzRZBweHSxc3nzJGF{e2G7 MViyNEDPxE1? M2DmNlQ5KGh? MYDEUXNQ M3Tx[Ilv\HWlZYOgZZBweHSxc3nz MUOyOFI5PjNzMh?=
HuH-7 NGLP[GNCeG:ydH;zbZMhSXO|YYm= M2HoSlIxKM7:TR?= MX20PEBp NYrzOJNJTE2VTx?= M4nt[olv\HWlZYOgZZBweHSxc3nz Mor6NlQzQDZ|MUK=
SMMC-7721  NHf2Om1HfW6ldHnvckBCe3OjeR?= NW\NcFRvOTBizszN MWmzOkBp NG\QdlVFVVOR NEPxSVZld3ewLYLl[5Vt[XSnczD0bIUheHKxdHXpckBmgHC{ZYPzbY9vKGyndnXsJI9nKHCqb4PwbI8uW2W{M{myMZA2Ow>? M4jUdVI1Ojh4M{Gy
HuH-7 MmrwSpVv[3Srb36gRZN{[Xl? NWGxSVlnOTBizszN MYOzOkBp NGKzTmlFVVOR M1PXNoRwf25vcnXneYxifGW|IITo[UBxem:2ZXnuJIV5eHKnc4Ppc44hdGW4ZXygc4YheGixc4Doc{1U\XJ|OUKtdFU{ MVeyOFI5PjNzMh?=
AT2 M{DXU2Z2dmO2aX;uJGF{e2G7 MWO1M|ExKM7:TR?= MlfCcIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhfGinIIC1N{Bxem:2ZXnuJIF{KHenbHygZZMhfGinIHX4dJJme3Orb36gc4YhcXS|IHTpdoVkfCC2YYLn[ZR{KHB{MTygUWROOiCjbnSgeIhmKHC{bz3hdI9xfG:2aXOgRmFZKGGwZDDQWW1CKHC{b4TlbY5{yqB? M{fGblI1OjRyMkCz
REH NXe1S5NMTnWwY4Tpc44hSXO|YYm= MkDsOU8yOCEQvF2= NXe1c2dxdGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZidHjlJJA2OyCycn;0[YlvKGG|IIflcIwh[XNidHjlJIV5eHKnc4Ppc44hd2ZiaYTzJIRqemWldDD0ZZJo\XS|IICyNUwhVUSPMjDhcoQhfGinIIDyc{1ieG:ydH;0bYMhSkG[IHHu[EBRXU2DIIDyc5RmcW6|wrC= NFfyXpUzPDJ2MEKwNy=>
UoCB6 M3TXS2Z2dmO2aX;uJGF{e2G7 NXnD[HlDPS9zMDFOwG0> NXLyVoc1dGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZidHjlJJA2OyCycn;0[YlvKGG|IIflcIwh[XNidHjlJIV5eHKnc4Ppc44hd2ZiaYTzJIRqemWldDD0ZZJo\XS|IICyNUwhVUSPMjDhcoQhfGinIIDyc{1ieG:ydH;0bYMhSkG[IHHu[EBRXU2DIIDyc5RmcW6|wrC= NUSxR2RpOjR{NECyNFM>
AT2 NG\zUm1E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGnPd4ExNTJ3IN88US=> M4fkUIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? M1fIc|I1OjRyMkCz
REH MoK4R4VtdCCYaXHibYxqfHliQYPzZZk> NFjBN2sxNTJ3IN88US=> MkfVbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NIT6bpkzPDJ2MEKwNy=>
UoCB6 M3W4bGNmdGxiVnnhZoltcXS7IFHzd4F6 MWWwMVI2KM7:TR?= Mn\pbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NXy5fGJZOjR{NECyNFM>
A2780 MmTCSpVv[3Srb36gRZN{[Xl? MWG1M|ExNzJyIN88US=> NFfTXoEzPCCq NWK0NHZDfXC{ZXf1cIF1\XNicEWzMEBOTE1{LDDwNlEh[W6mIFTSOUBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7wrC= MkPJNlQyOzZzNEe=
H460 MmT5SpVv[3Srb36gRZN{[Xl? MWm1M|ExNzJyIN88US=> MlzFNlQhcA>? MVn1dJJm\3WuYYTld{BxPTNuIF3EUVItKHB{MTDhcoQhTFJ3IIDyc5RmcW5ibHX2[Yx{KGSxc3Wg[IVx\W6mZX70cJnDqA>? MVmyOFE{PjF2Nx?=
Lovo  NYfG[HNyTnWwY4Tpc44hSXO|YYm= MXy1M|ExNzJyIN88US=> MVqyOEBp M1XuXZVxemWpdXzheIV{KHB3MzygUWROOixicEKxJIFv\CCGUkWgdJJwfGWrbjDs[ZZmdHNiZH;z[UBl\XCnbnTlcpRtgcLi NGjXPHAzPDF|NkG0Oy=>
A2780 NFW3[olCeG:ydH;zbZMhSXO|YYm= MoSwOU8yOC9{MDFOwG0> MWeyOEBp MlHo[Y5p[W6lZYOgZZBweHSxc3nzJIlv\HWldHnvckBjgSCGMk[5TE9GOTl3UjDveoVzKHKqVGLBTWw> MYCyOFE{PjF2Nx?=
H460 MkXwRZBweHSxc3nzJGF{e2G7 MXK1M|ExNzJyIN88US=> NFHESGMzPCCq M4PTNYVvcGGwY3XzJIFxd3C2b4Ppd{BqdmS3Y4Tpc44h[nliREK2PWgwTTF7NWKgc5ZmeiC{aGTSRWlN NHL4NG4zPDF|NkG0Oy=>
Lovo  Mn\2RZBweHSxc3nzJGF{e2G7 NV7rZ2l{PS9zMD:yNEDPxE1? MlSwNlQhcA>? NEPrW2tmdmijbnPld{BieG:ydH;zbZMhcW6mdXP0bY9vKGK7IFSyOllJN0VzOUXSJI93\XJicnjUVmFKVA>? NYDzcnFUOjRzM{[xOFc>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい
体内試験 Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

お薦めの試験操作（参考用のみ）

キナーゼ試験：

[1]
+ 展開

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
細胞試験：

[1]
+ 展開
  • 細胞株： HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • 濃度： Dissolved in DMSO, final concentrations ~ 30 μM
  • 反応時間： 8, 24, and 48 hours
  • 実験の流れ：

    Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.


    (参考用のみ)
動物試験：

[1]
+ 展開
  • 動物モデル： Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • 製剤： Formulated in 2% Klucel, 0.5% Tween 80
  • 投薬量： 200 mg/kg
  • 投与方法： Orally, twice a day
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 581.5
化学式

C30H30Cl2N4O4
CAS No. 890090-75-2
保管 粉
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

総分子量：g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問（FAQ）

  • 質問1：

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • 回答：

    It is a racemate.

selleck catalog

Mdm2シグナル伝達経路

相関Mdm2製品

  • MI-773 (SAR405838)

    MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

  • A-1210477

    A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.

  • NSC 207895

    NSC 207895 suppresses MDMX with IC50 of 2.5 μM, leading to enhanced p53 stabilization/activation and DNA damage, and also regulates MDM2, an E3 ligase.

  • Nutlin-3a

    Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.

    Features:Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.

  • Nutlin-3b

    Nutlin-3b is a p53/MDM2 antagonist or inhibitor with IC50 value of 13.6 μM, 150-fold less potent (+)-enantiomer of Nutlin-3 as in comparison with opposite (-)-enantiomer Nutlin-3a.

  • YH239-EE

    YH239-EE, the ethyl ester of YH239, is a potent p53-MDM2 antagonist and an apoptosis inducer.

  • Z-VAD-FMK

    Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

    Features:A key compound for apoptosis studies.

Tags: Nutlin-3を買う | Nutlin-3 ic50 | Nutlin-3供給者 | Nutlin-3を購入する | Nutlin-3費用 | Nutlin-3生産者 | オーダーNutlin-3 | Nutlin-3化学構造 | Nutlin-3分子量 | Nutlin-3代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID